A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Transgene
- Target Recruit Count
- 36
- Registration Number
- NCT05788926
- Locations
- 🇫🇷
Hôpital Européen Georges Pompidou, Paris, France
🇫🇷Institut Bergonié, Bordeaux, France
🇫🇷Hôpital Timone, Marseille, France
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Transgene
- Target Recruit Count
- 48
- Registration Number
- NCT04725331
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Hôpital Saint-Louis AP-HP, Paris, France
Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- Transgene
- Target Recruit Count
- 15
- Registration Number
- NCT04194034
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷Institut Gustave Roussy, Villejuif, France
🇬🇧NHS St James's University Hospital, Leeds, United Kingdom
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Transgene
- Target Recruit Count
- 80
- Registration Number
- NCT04183166
- Locations
- 🇪🇸
Hospital Universitari Vall d Hebrón, Barcelona, Spain
🇪🇸Institut Català d Oncologia - Hospital Duran i Reynals, Barcelona, Spain
🇪🇸Hospital Clínico San Carlos, Madrid, Spain
A Trial Evaluating TG4050 in Ovarian Carcinoma.
- Conditions
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Transgene
- Target Recruit Count
- 64
- Registration Number
- NCT03839524
- Locations
- 🇫🇷
IUCT Toulouse, Toulouse, France
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
🇫🇷Hôpital Pitié-Salpêtrière, Paris, France
Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.
- Conditions
- Interventions
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- Transgene
- Target Recruit Count
- 51
- Registration Number
- NCT03724071
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇧🇪Institut Jules Bordet, Brussels, Belgium
🇫🇷IUCT Toulouse, Toulouse, France
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2017-11-27
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Transgene
- Target Recruit Count
- 44
- Registration Number
- NCT03353675
- Locations
- 🇺🇸
Charlotte, Charlotte, North Carolina, United States
🇫🇷Créteil, Créteil, France
🇺🇸Nashville, Nashville, Tennessee, United States
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
- Conditions
- Interventions
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Transgene
- Target Recruit Count
- 150
- Registration Number
- NCT03260023
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇫🇷I.C.O. Paul Papin, Angers, France
🇫🇷CHU Besançon, Besançon, France
A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Transgene
- Target Recruit Count
- 14
- Registration Number
- NCT03071094
- Locations
- 🇫🇷
Site No 0101, Paris, France
🇫🇷Site No 0102, Nancy, France
Safety and Tolerability of TG1050: A Dose-finding Study
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Transgene
- Target Recruit Count
- 48
- Registration Number
- NCT02428400